18 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
The Occurrence of Adverse Events Following Costal Bone Marrow Aspiration Classified by Calvien DindoPrimary· 7 days following surgery
All adverse events will be classified by the Clavien Dindo classification. The study will be closed prematurely if 2 patients experience a grade 3 adverse event directly related to the bone marrow aspiration
Group
Value
95% CI
Costal Bone Marrow Aspiration
6
2 – 11
Adverse events — posted to ClinicalTrials.gov
Time frame: all adverse events were captured from signing the ICF till 30 days post surgery.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This pilot trial is designed to evaluate the feasibility and safety of obtaining bone marrow from costal aspiration during surgery.
The investigators hypothese that sufficient bone marrow-derived HSPC's (which represent only 0,1% of the total bone marrow fraction) can be derived by rib bone marrow aspiration for ex vivo single-cell evaluation, optimization of a 3D BMN platform and preclinical ex/in vivo assessment in patient-derived organoids and murine xenograft models.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno
· Phase 2
· recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
· Phase 1
· recruiting
NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL
· Phase 2
· recruiting
NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
· Phase 2
· recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas
· Phase 2
· recruiting
Other Universitair Ziekenhuis Brussel trials
Trials by the same sponsor.
NCT07536230 — Deep Learning Framework for Continuous Depth of Anesthesia Forecasting
· not yet recruiting
NCT07533968 — The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in I
· NA
· not yet recruiting
NCT07289984 — Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders and
· NA
· not yet recruiting
NCT06923813 — Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calo
· NA
· recruiting
NCT07401004 — Effect of Blink-Based Training on Cancer Detection in Colorectal Polyp Images by Medical Students/Non GI-trainees
· NA
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universitair Ziekenhuis Brussel
Last refreshed: 8 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05251805.